Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O43159
UPID:
RRP8_HUMAN
Alternative names:
Cerebral protein 1; Nucleomethylin
Alternative UPACC:
O43159; Q7KZ78; Q9BVM6
Background:
Ribosomal RNA-processing protein 8, also known as Cerebral protein 1 and Nucleomethylin, plays a pivotal role in the eNoSC complex, crucial for rDNA silencing in response to cellular energy levels. This process involves histone modifications, including H3 deacetylation and H3K9me2 dimethylation, leading to the formation of silent chromatin at the rDNA locus. RRP8's specific function within this complex includes binding to H3K9me2 and potentially acting as a methyltransferase.
Therapeutic significance:
Understanding the role of Ribosomal RNA-processing protein 8 could open doors to potential therapeutic strategies.